PDF(Pubmed)
Abstract：
BACKGROUND: IL-6 is a pleiotropic cytokine modulating inflammation and metabolic pathways. Its proinflammatory effect plays a significant role in organ failure pathogenesis, commonly elevated in systemic inflammatory conditions. Extracorporeal blood purification devices, such as the Advanced Organ Support (ADVOS) multi hemodialysis system, might offer potential in mitigating IL-6\'s detrimental effects, yet its efficacy remains unreported.
METHODS: We conducted a proof-of-concept in vitro study to assess the ADVOS multi system\'s efficacy in eliminating IL-6. Varying concentrations of IL-6 were introduced into a swine blood model and treated with ADVOS multi for up to 12 h, employing different blood and concentrate flow rates. IL-6 reduction rate, clearance, and dynamics in blood and dialysate were analyzed.
RESULTS: IL-6 clearance rates of 0.70 L/h and 0.42 L/h were observed in 4 and 12-h experiments, respectively. No significant differences were noted across different initial concentrations. Reduction rates ranged between 40 and 46% within the first 4 h, increasing up to 72% over 12 h, with minimal impact from flow rate variations. Our findings suggest that an IL-6-albumin interaction and convective filtration are implicated in in vitro IL-6 elimination with ADVOS multi.
CONCLUSIONS: This study demonstrates for the first time an efficient and continuous in vitro removal of IL-6 by ADVOS multi at low blood flow rates. Initial concentration-dependent removal transitions to more consistent elimination over time. Further clinical investigations are imperative for comprehensive data acquisition.
METHODS: We conducted a proof-of-concept in vitro study to assess the ADVOS multi system\'s efficacy in eliminating IL-6. Varying concentrations of IL-6 were introduced into a swine blood model and treated with ADVOS multi for up to 12 h, employing different blood and concentrate flow rates. IL-6 reduction rate, clearance, and dynamics in blood and dialysate were analyzed.
RESULTS: IL-6 clearance rates of 0.70 L/h and 0.42 L/h were observed in 4 and 12-h experiments, respectively. No significant differences were noted across different initial concentrations. Reduction rates ranged between 40 and 46% within the first 4 h, increasing up to 72% over 12 h, with minimal impact from flow rate variations. Our findings suggest that an IL-6-albumin interaction and convective filtration are implicated in in vitro IL-6 elimination with ADVOS multi.
CONCLUSIONS: This study demonstrates for the first time an efficient and continuous in vitro removal of IL-6 by ADVOS multi at low blood flow rates. Initial concentration-dependent removal transitions to more consistent elimination over time. Further clinical investigations are imperative for comprehensive data acquisition.
摘要：
背景：IL-6是调节炎症和代谢途径的多效性细胞因子。其促炎作用在器官衰竭的发病机制中起着重要作用，通常在全身性炎症中升高。体外血液净化装置,例如高级器官支持（ADVOS）多血液透析系统，可能提供减轻IL-6有害影响的潜力，但其疗效仍未报告。
方法：我们进行了一项体外概念验证研究，以评估ADVOS多系统在消除IL-6方面的功效。将不同浓度的IL-6引入猪血模型中，并用ADVOS多药处理长达12小时，采用不同的血液和浓缩液流速。IL-6降低率，间隙,并对血液和透析液中的动力学进行了分析。
结果：在4和12小时实验中观察到IL-6清除率为0.70L/h和0.42L/h，分别。在不同的初始浓度之间没有注意到显著差异。在最初的4小时内，减少率介于40％和46％之间，在12小时内增加高达72%，从流量变化的影响最小。我们的发现表明，IL-6-白蛋白相互作用和对流过滤与ADVOS多重体外IL-6消除有关。
结论：这项研究首次证明了在低血流速率下，ADVOSmulti在体外有效且连续地去除IL-6。随着时间的推移，初始浓度依赖性去除过渡到更一致的消除。进一步的临床研究对于全面的数据采集至关重要。
方法：我们进行了一项体外概念验证研究，以评估ADVOS多系统在消除IL-6方面的功效。将不同浓度的IL-6引入猪血模型中，并用ADVOS多药处理长达12小时，采用不同的血液和浓缩液流速。IL-6降低率，间隙,并对血液和透析液中的动力学进行了分析。
结果：在4和12小时实验中观察到IL-6清除率为0.70L/h和0.42L/h，分别。在不同的初始浓度之间没有注意到显著差异。在最初的4小时内，减少率介于40％和46％之间，在12小时内增加高达72%，从流量变化的影响最小。我们的发现表明，IL-6-白蛋白相互作用和对流过滤与ADVOS多重体外IL-6消除有关。
结论：这项研究首次证明了在低血流速率下，ADVOSmulti在体外有效且连续地去除IL-6。随着时间的推移，初始浓度依赖性去除过渡到更一致的消除。进一步的临床研究对于全面的数据采集至关重要。
